Biosimilars are not a problem when it comes to the
Post# of 147858
(Total Views: 438)
Posted On: 09/25/2021 10:35:18 PM
Re: chuckles759 #105742
Biosimilars are not a problem when it comes to the 12 year exclusivity. The exclusivity is based on the active moiety of the drug a biosimilar would infringe on that. Not having to do phase 3 and phase 4 trials is aimed at generics and biosimilars after the 12 year exclusivity is done.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼